- A +

Events › 2017

19 - 22Jun.2017

BIO International ConventionSan Diego, CA US

GenSight will attend and host partnering meetings. 

27May2017

5th Annual ARM Cell&Gene Investor Day, Boston (MA), US

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present at the ARM Cell&Gene Investor Day in Boston, MA, USA on Thursday, March 27, 2017, at 4:45 pm ET, The Great Room, and will host investor meetings.

07 - 11May2017

2017 ARVO Annual Meeting, Baltimore, Maryland (US)

GenSight will attend the annual meeting 2017 ARVO. 

 

 

03 - 04May2017

Deutsche Bank 42nd Annual Health Care Conference, Boston (MA), US

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present at the Deutsche Bank 42nd Annual Health Care Conference in Boston, MA, USA and will host investor meetings.

22 - 28Apr.2017

American Academy of Neurology 69th Annual Meeting (AAN)

GenSight will give an oral presentation entitled "Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber's Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation" (Abstract number #2444) in Session S26: Neuro-ophthalmology/Neuro-Otology on April 25, 2017, at 4:18 PM (platform presentation number  005).

01 - 06Apr.2017

43rd NANOS Annual Meeting (North American Neuro-Ophthalmology Society)

GenSight will give an oral presentation and present two posters on its lead product GS010 currently in Phase 3 in Europe and US aiming at treating LHON, a rare mitochondrial genetic disease

Both posters will be presented at the session “Poster Session II: Scientific Advancements in Neuro-Ophthalmology” in the Category: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) on Tuesday, April 4, 2017 from 6:00 -9:30 pm, Room Location: Exhibit Hall C

Title:  Pediatric Leber Hereditary Optic Neuropathy (LHON): A Literature Review (Poster Number # 186)

Title:  Preliminary Baseline Characteristics of Patients with LHON Enrolled in RESCUE and REVERSE Gene Therapy Trials (Poster Number # 189)

Presentation will take place on Tuesday, April 4th from 10:00am- 10:15am, in the Thurgood Marshall Ballroom

Title:  Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, Investigational Gene Therapy for ND4 LHON.

09 - 12Nov. - Jan.2017

JP Morgan 35th Annual Healthcare Conference, San Francisco (CA), USA

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings. GenSight took this opportunity to meet with a numerous partners and companies. 

05 - 06Jan.2017

Oddo 20th Forum – Lyon, France

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings at the 20th Oddo Forum in Lyon, France on January 5-6, 2017